Retatrutide studies
337 journal papers mention Retatrutide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Retatrutide is safe, effective or approved for any use.
- Papers
- 337
- 211 articles, 126 reviews
- Earliest paper
- 2019
- Most papers in 2026 (163)
- Open access
- 67%
- free to read somewhere
- Reviews
- 37%
- of all papers listed
What kind of studies
Of 214 papers in PubMed that mention Retatrutide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials10
- Other clinical trials1
- Meta-analyses and systematic reviews23
- Other reviews131
- Case reports3
- Animal studies only11
- Studies in humans129
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Registered clinical studies
Studies on ClinicalTrials.gov that mention Retatrutide in their intervention details. A registration says a study is planned or running, not what it found.
- Registered
- 34
- Completed
- 22
- Ongoing or planned
- 11
- Phase 1
- 15
- Phase 2
- 4
- Phase 3
- 14
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390Active, not recruitingPhase 3started 2024-04-30
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028RecruitingPhase 3started 2025-10-15
- A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
NCT06982859Active, not recruitingPhase 1started 2025-06-02
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
NCT06260722Active, not recruitingPhase 3started 2024-02-21
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093Active, not recruitingPhase 3started 2025-05-29
The five most recently updated studies. See all 34 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.
Papers per year
2019 to 2026, peak 163 papers in a year. The latest year may still be incomplete.
Where it is published
- Diabetes22 papers
- Diabetes Obesity and Metabolism8 papers
- Cureus7 papers
- Quality in Sport7 papers
- International Journal of Innovative Technologies in Social Science6 papers
The papers
Most citedName in the title
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
Manmeet Kaur, Saurav Misra · European Journal of Clinical Pharmacology · 2024
Review51 citations
- Retatrutide—A Game Changer in Obesity Pharmacotherapy
Vasiliki K. Katsi, Georgios Koutsopoulos, Christos Fragoulis et al. · Biomolecules · 2025
ReviewOpen access · CC BY29 citationsRead the open copy →
- The power of three: Retatrutide's role in modern obesity and diabetes therapy
Toufik Abdul‐Rahman, Poulami Roy, Fatma Kamal Ahmed et al. · European Journal of Pharmacology · 2024
Review27 citations
- Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Alaa Abdrabou Abouelmagd, Amro Mamdouh Abdelrehim, Mohamed Nabih Bashir et al. · Baylor University Medical Center Proceedings · 2025
ReviewOpen access25 citationsRead the open copy →
- Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials
Eric Pasqualotto, Rafael Oliva Morgado Ferreira, Matheus Pedrotti et al. · Metabolism Open · 2024
ReviewOpen access · CC BY15 citationsRead the open copy →
- Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis
Jay Tewari, Khalid Ahmad Qidwai, Ajoy Tewari et al. · Expert Review of Clinical Pharmacology · 2025
Meta-analysis9 citations
- The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
Nila Ganamurali, Sarvesh Sabarathinam · Clinical Pharmacology in Drug Development · 2026
ReviewOpen access · Public domain8 citationsRead the open copy →
LatestName in title or abstract
- EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW
Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026
ReviewOpen accessRead the open copy →
- Glucose-dependent insulinotropic polypeptide (GIP) signaling in visceral and subcutaneous adipose tissue: implications for obesity and metabolic disease—a narrative review with a structured literature search
Joanna Smarkusz-Zarzecka, Marcelina Radziszewska, Krzysztof Ksawery Gofron et al. · Reviews in Endocrine and Metabolic Disorders · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- Effects of GLP-1–Related Therapies on Lean Mass and Body Composition: A Narrative Review
Amanda Palmieri Ataei, Nima Ataei · Journal of Fitness Wellness and Human Performance · 2026
Review
- GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?
Ademir Carvalho Leite, Howard Lopes Ribeiro · Acta Diabetologica · 2026
ReviewOpen access · CC BYRead the open copy →
- From pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease
Christiano Argano, Dalila Maggio, Chiara Pollicino et al. · Frontiers in Pharmacology · 2026
ReviewOpen access · CC BYRead the open copy →
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications
Zhiyu Chen, Ying Zhou, Gang Li et al. · Journal of Diabetes & Metabolic Disorders · 2026
ReviewOpen accessRead the open copy →
- Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective
Ishtiaque Ahmad, Sarfuddin Azmi, Monirah Abdulrahman Albabtain et al. · Pharmaceutics · 2026
ReviewOpen access · CC BYRead the open copy →
- Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence
Diana-Maria Mateescu, Ionuţ Dragoş Căpraru, Bogdan Enache et al. · Pharmaceutics · 2026
ReviewOpen access · CC BYRead the open copy →
- GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases
Elena Koceva, Gert N. Moll · European Journal of Pharmacology · 2026
ReviewOpen access · CC BYRead the open copy →
- GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity–Neurodegeneration Interface: A Narrative Review
Elena Popa, Andrei Emilian Popa, Vladimir Poroch et al. · International Journal of Molecular Sciences · 2026
ReviewOpen access · CC BYRead the open copy →
- Gastrointestinal adverse effects of GLP‐1 receptor agonists and dual GIP/GLP‐1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents
Fnu Vikash, Muhammad Ehsan, Sara Osorio Valencia et al. · Nutrition in Clinical Practice · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis
Muhammad Maaz Amjad, Muhammad Mustafa Khan, Fatima Sarwar et al. · Diabetes Obesity and Metabolism · 2026
ReviewOpen accessRead the open copy →
- The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?
Maja Mizdrak, Darko Batistic, Ivan Mizdrak · Medical Sciences · 2026
ReviewOpen access · CC BYRead the open copy →
- Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists
Dorota Bartkowiak, Barlomiej Jakubczyk, Adam Lasota et al. · Cureus · 2026
ReviewOpen access · CC BYRead the open copy →
- Single or multiple nutritional hormone receptor modulators for chronic kidney disease
Hiddo J.L. Heerspink · Clinical Kidney Journal · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review
Irma Melyani Puspitasari, Dimas Setyadi Putra, Alifa Nisa Deliyana et al. · Diabetes Metabolic Syndrome and Obesity · 2026
ReviewOpen access · CC BY-NCRead the open copy →
Each list shows up to 40 papers.See all 337 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:30 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.